No abstract available.
Graft Survival* ; Kidney* ; Transplants*

No abstract available.
Graft Survival* ; Kidney* ; Transplants*

No abstract available.
Graft Survival* ; Transplants*

No abstract available.
Cyclosporine* ; Graft Survival* ; Kidney* ; Transplants*

No abstract available.
Allografts* ; Graft Survival* ; Humans ; Transplants*

No abstract available.
Allografts* ; Cyclosporine* ; Graft Survival* ; Transplants*

No abstract available.
Allografts* ; Cyclosporine* ; Graft Survival* ; Transplants*

PURPOSE: To conform the effectiveness of Cyclosporin(CsA) in penetrating keratoplasty(PKP), we compared the survival rate of grafts between CsA-used group and CsA-unused group(control group) in high risk patients. MATERIAL AND METHOD: High risk cornea was defined as vascularization in 3 or 4 quadrants, recurrent graft or corneal surface disease. We reviewed the 74 eyes(74 patients) which received penetrating keratoplasty with high risk cornea, and compared the survival rate between CsA-used group and control group. RESULT: Twenty-nine of the 74 patients were treated with CsA(17 patients with topical CsA and 12 with oral CsA ). The survival rate of CsA-used group was not superior to that of control group. CONCLUSION: CsA seems not to be effective in graft survival of high risk PKP.
Cornea ; Cyclosporine* ; Graft Survival ; Humans ; Keratoplasty, Penetrating* ; Survival Rate ; Transplants

Non-vascularized free composite graft is one of the simple and effective reconstructive options, but its clinical use has been limited due to questionable survival rate. Early vascularization is essential for graft survival and is mainly carried out via recipient bed or repaired sites. This study was designed to investigate the effect of the lateral marginal approximations on the survival of the free composite flap using a model of skin-subcutaneous composite graft in rats. Thirty 1.5 x 1.5 cm2 sized square shape composite flaps were elevated freely and reposed in place immediately on the dorsum of five Sprague-Dawley rats, and divided into five groups of six flaps. In all groups, graft bed was isolated with silastic sheet. In the group I, all sides of flap were repaired with blockage of silastic sheet insertion. Three, two, and one sides of flap were treated with same method in the group II, III, and IV respectively. Other sides of flaps were repaired without blockage, so all sides of flap were repaired in the group V. At 14 days later, the survived rate of each flap was evaluated according to the numbers of the repair sites. Histological examination was done for the evaluation of new vessel development quantitatively. Overall survived rates were increased with the number of repaired sites, but the group V only showed increased survival rate up to more than fifty percentile of the flap size with a significant difference statistically. New vessels were also increased in proportion with the number of repaired sites, and the repair site more than two had significant effect on the increased number of new vessels. In conclusion, at least more than threefourth of flap circumference should be repaired in order to increase flap survival effectively under the condition of bed isolation.
Animals ; Graft Survival ; Rats ; Rats, Sprague-Dawley ; Survival Rate ; Transplants

Antibody-mediated rejection (AMR) is a rare and serious complication after lung transplantation, with no characteristic of pathological manifestation, no systematic standard treatment, and the poor efficacy and prognosis. We reported a case of early AMR after lung transplantation and the relevant literature has been reviewed. A male patient presented with symptoms of cold 99 days after transplantation and resolved after symptomatic treatment. He admitted to the hospital 14 days later because of a sudden dyspnea and fever. Anti-bacteria, anti-fungi, anti-virus, and anti-pneumocystis carinii treatment were ineffective, and a dose of 1 000 mg methylprednisolone did not work too. The patient's condition deteriorated rapidly and tracheal intubation was done to maintain breathing. Serum panel reactive antibody and donor specific antibody showed postive in humen leukocyte antigen (HLA) II antibody. Pathological examination after transbronchial transplantation lung biopsy showed acute rejection. Clinical AMR was diagnosed combined the donor-specific antibody with the pathological result. The patient was functionally recovered after combined treatment with thymoglobuline, rituximab, plasmapheresis, and immunoglobulin. No chronic lung allograft dysfunction was found after 3 years follow up. We should alert the occurrence of AMR in lung transplantation recipient who admitted to hospital with a sudden dyspnea and fever while showed no effect after common anti-infection and anti-rejection treatment. Transbronchial transplantation lung biopsy and the presence of serum donor-specific antibody are helpful to the diagnosis. The treatment should be preemptive and a comprehensive approach should be adopted.
Graft Rejection ; Graft Survival ; HLA Antigens ; Humans ; Isoantibodies ; Lung Transplantation/adverse effects* ; Male